- Home
- SABA vs NBP Comparison
SABA vs NBP Comparison
Compare SABA & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SABA | NBP |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.3M | 212.8M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SABA | NBP |
|---|---|---|
| Price | $8.23 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 44.5K | ★ 262.6K |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | ★ 12.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $1.46 |
| 52 Week High | $9.30 | $5.19 |
Technical Indicators
Market Signals| Indicator | SABA | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 47.14 |
| Support Level | $8.19 | $1.78 |
| Resistance Level | $8.42 | $1.98 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 85.19 | 28.57 |
Price Performance
Historical ComparisonAbout SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.